We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.2998 | 1.08% | 28.0698 | 28.34 | 27.52 | 27.70 | 39,007,274 | 23:09:27 |
From May 2019 to May 2024
By Stephen Nakrosis
Pfizer Inc. (PFE) said Thursday the U.S. Food and Drug Administration approved Xeljanz extended-release tablets for adult patients with moderately to severely active ulcerative colitis.
Pfizer said its extended-release 11 mg and 22 mg tablets of Xeljanz, or tofacitinib, was indicated "for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers."
Xeljanz is also indicated for the treatment of Rheumatoid Arthritis and Psoriatic Arthritis, the company said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 12, 2019 18:28 ET (23:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
